Efficacy of VAB (Vonoprazan, Amoxicillin and Bismuth subsalicylate) versus standard triple therapy for Helicobacter pyroli eradication: A randomized controlled trial

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210928005

Enrollment

160

Registered

2021-09-28

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pyroli eradication rate by VAB (Vonoprazan, Amoxicillin and Bismuth subsalicylate) regimen Helicobacter pylori Bismuth subsalicylate

Interventions

Participants are received Vonoprazan 20 mg oral bid pc, Amoxicillin 1 g oral bid pc and Bismuth subsalicylate 1 g bid pc for 7 days,Participants are received Omeprazole 20 mg oral bid ac, Amoxicillin

Active Comparator Drug,Active Comparator Drug

VAB therapy,Standard triple therapy

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 20 years, Postive test of H. pylori infection (Urea breath test, Stool Ag test, EGD with Rapid urease test or Tissue pathology) with agreement

Exclusion criteria

Exclusion criteria: Active upper gastrointestinal bleeding, eGR < 30 ml/min/1.73m2, drug allergy, pregnancy or lactation, hemodynamic instability, previous treatment of H. pylori infection, HIV infection, Neuroendocrine tumor

Design outcomes

Primary

Measure	Time frame
Eradication rate 4 week after treatment each group Helicobacter pylori assessment by Urea breath test or stool Ag test or EGD with rapid urease test	—

Secondary

Measure	Time frame
Adverse drug reaction During treatment each group Side effect	—

Countries

Thailand

Contacts

Public ContactThitiwat Phetkee

Phramongkutklao hospital

thitiwat.phetkee@gmail.com0836237363

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026